Skip to content

Abstract B172: Comparing pathogenic variants (PV) and variants of uncertain significance (VUS) in breast cancer (BC) susceptibility genes by genetic similarity groups among WISDOM 2.0 participants

Oct 2026 · Cancer Epidemiology, Biomarkers & Prevention · 0 citations

TL;DR

Findings provide population-scale evidence that current reference databases underserve non-European populations, highlighting an urgent need to diversify genomic datasets to ensure equitable variant classification in clinical risk-based screening.

Abstract

WISDOM (Women Informed to Screen Depending On Measures of risk), a study of risk-based breast cancer (BC) screening, is the first to deploy population-based germline testing for high- and intermediate-penetrance BC genes. Given that genomic reference databases remain disproportionately European in ancestry, VUS detection rates are known to be higher in non-European populations, undermining equitable, personalized risk assessment. We used single nucleotide variants (SNVs) to infer genetic similarity to reference populations and evaluated variant classification and frequency by genetic similarity groups across the WISDOM cohort. We analyzed sequencing data from 17,930 WISDOM 2.0 participants with qualifying test results across 12 BC susceptibility genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53), classifying variants as pathogenic (P), likely pathogenic (LP), or of uncertain significance (VUS). Genetic similarity was estimated using 1000 Genomes dataset as a reference, including 5 meta-populations: African (AFR), East Asian (EAS), European (EUR), Mixed American (AMR), or South Asian (SAS). We used data ∼100,000 independent SNVs (R2<0.10) and ran principal components analysis (PCA). We then projected WISDOM participants into predetermined cutoffs to identify each participant as most like one of 5 populations. We compared P/LP frequencies across all groups with Fisher's exact test; VUS proportions with chi-squared tests. PCA analyses were conducted in PLINK and all statistical tests were run as heterogeneity tests including all groups using R. Of the 17,930 participants, 336 (1.9%) carried a P/LP variant and 1,323 (7.4%) carried a VUS in at least one gene, including 158 (1.0%) in CHEK2. VUS burden varied significantly (p=0.0005) by genetic similarity group: EAS participants had the highest (88/765, 11.5%), followed by AFR (93/891, 10.4%), AMR (94/917, 10.3%), and SAS (15/159, 9.4%) all higher than EUR (1,033/15,198, 6.8%). There was also significant heterogeneity (p=0.01) in the rate of P/LP variants by genetic similarity group. EUR participants had the highest rate of P/LP variants (305/15198, 2.0%), comparable to SAS (3/159, 1.9%) and AFR (15/891, 1.7%), and higher than EAS (8/765, 1.0%) and AMR (7/917, 0.8%). The P/LP variants in CHEK2 were particularly high in EUR participants (1.0%) and driven by 3 founder mutations compared to other genetic similarity groups. P/LP rates for other genes did not differ significantly by genetic similarity group. In this pragmatic screening trial, P/LP detection rates were highest in EUR genetic similarity participants, largely driven by CHEK2 founder variants, while VUS rates were higher across all non-EUR groups and most pronounced in EAS participants. These findings provide population-scale evidence that current reference databases underserve non-European populations, highlighting an urgent need to diversify genomic datasets to ensure equitable variant classification in clinical risk-based screening. Jackelyn J. Moya, Daisy Montoya, Allison Fiscalini, Irene Acerbi Soto, Yaruska Ordinola Perez, Kirk Fergus, Yiwey Shieh, Katherine Ross, Deborah Goodman, Dezheng Huo, Donglei Hu, Funmi Olopade, Jeff Tice, Diane Heditsian, Dolores Moorehead, Laura Esserman, Lisa Madlensky, Elad Ziv. Comparing pathogenic variants (PV) and variants of uncertain significance (VUS) in breast cancer (BC) susceptibility genes by genetic similarity groups among WISDOM 2.0 participants [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr B172.

View source

Similar papers

Oct 2026

Abstract B076: Germline variation in cancer susceptibility genes among Black cancer survivors in the Reclassifying Variants for Equity in Clinical Care (REVEAL) study

A high burden of VUS among Black cancer survivors is shown and opportunities for systematic VUS reclassification are highlighted to highlight opportunities for systematic reclassification.

Shao-Miao Xia, Yue Zhao, A. Scott et al. · 0 citations
Open access 2026

Reclassification of variants of uncertain significance in genes associated with hereditary breast cancer in patients treated at referral hospitals in the state of Goiás

Introduction: Breast cancer is the most common malignancy among women, with 5–10% of cases arising from hereditary predisposition, driven by pathogenic variants in DNA repair genes such as BRCA1/BRCA2, as well as moderate-risk genes, including ATM, CHEK2, TP53, BARD1, and BRIP1. Next-generation sequencing improves vari...

B. F. Nascimento, I. M. Calassa, Luiz Henrique Alves Costa et al. · 0 citations
Oct 2026

Abstract B043: Population genetics of rare coding variants at HOXB13 and their relevance to prostate cancer risk in sub-Saharan Africa

Rare HOXB13 variants have been associated with early-onset and aggressive prostate cancer, yet their evolutionary significance remains poorly understood in African populations where disease burden is highest. We analyzed genotype data from 3,963 cases and 3,509 controls across Ghana, Nigeria, Senegal, Sout...

Rohini Janivara, I. Lauder, A. Rajesh et al. · 0 citations
Open access 2026

Importance of reclassification of variants of uncertain significance in patients with breast cancer using multigene panel testing

The reclassification of VUS demonstrated a direct impact on genetic interpretation and risk stratification in patients with breast cancer, and the identification of likely pathogenic variants reinforces the importance of appropriate clinical follow-up for patients and their families.

J. F. Tavares, Paula Francinete Faustino da Silva, B. F. Nascimento et al. · 0 citations
Review Open access Sep 2026

Interpreting TP53 pathogenic variants in germline testing and cancer genomics: pathogenicity, origin, and clinical actionability.

An origin-aware, three-layer framework comprising variant pathogenicity assessment, origin attribution, and clinical actionability is proposed to support proportionate surveillance, cascade testing, and shared decision-making.

I. Imoto, Nobue Takaiso, A. Yoshimura · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.